Cargando…

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia

OBJECTIVE: To compare the cost-effectiveness of long-acting insulin analogue (LAIA) (insulin Detemir and insulin Glargine) versus NPH insulin in the basal insulin regime for naïve insulin T2DM Malaysian patients. METHODS: The UKPDS-Outcome Model version 2.0 (UKPDS-OM2) was used to evaluate the cost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafie, Asrul Akmal, Ng, Chin Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319511/ https://www.ncbi.nlm.nih.gov/pubmed/32606850 http://dx.doi.org/10.2147/CEOR.S244884

Ejemplares similares

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
por: Davies, M. J., et al.
Publicado: (2016)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Esposito, Katherine, et al.
Publicado: (2012)

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK
por: Husemoen, Lise Lotte Nystrup, et al.
Publicado: (2021)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
por: Rosenstock, J., et al.
Publicado: (2008)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Open‐label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin‐naïve Asian patients with type 2 diabetes
por: Hirose, Takahisa, et al.
Publicado: (2017)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
por: Lv, Wen-shan, et al.
Publicado: (2013)

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
por: Pan, Changyu, et al.
Publicado: (2016)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
por: Rodbard, H W, et al.
Publicado: (2013)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery
por: Ahmad, Mushtaq, et al.
Publicado: (2015)

Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study
por: Damci, Taner, et al.
Publicado: (2014)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens
por: Yavuz, Dilek Gogas, et al.
Publicado: (2015)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_22qn6g52m4s8su1cjal3vs1smg